File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Antithyroid drugs in the treatment of hyperthyroidism of Graves'disease: Long-term follow-up of 434 patients

TitleAntithyroid drugs in the treatment of hyperthyroidism of Graves'disease: Long-term follow-up of 434 patients
Authors
Issue Date1989
PublisherWiley-Blackwell Publishing Ltd.. The Journal's web site is located at http://www.wiley.com/bw/journal.asp?ref=0300-0664
Citation
Clinical Endocrinology, 1989, v. 31 n. 2, p. 209-218 How to Cite?
AbstractA study of antithyroid (ATD) therapy with a mean follow-up period of 10 years (range 2-25) in 434 patients with Graves'diseases has been made by linking hospital records with those of a central follow-up register. The majority (89%) were treated with carbimazole and 87% received combined therapy with triiodothyronine (T3) (73%) or thyroxine (T4) (14%). Sixty-one per cent were assessed for T3 suppression tests on completion of treatment, of whom 61% (95% CL, 55-67%) suppressed. The overall 5-year cumulative proportion developing recurrent hyperthyroidism was 54-62% with rates of 26-44% in suppressed patients and 65-79% in those not suppressed. In unsuppressed patients, most (72%) of the recurrences occurred within 1 year with only an additional 10% predicted up to 10 years. In suppressed patients 30% of recurrences occurred in the first year, 60% between 1 and 5 years and a further 10% between 5 and 10 years. Suppression with T3 is probably the best and cheapest predictor of outcome but has an accuracy of only 70% for both positive and negative tests which limits its usefulness in planning long-term follow-up and surveillance. A standard format should be adopted for the analysis and reporting of follow-up studies, based on actuarial methods of estimating the cumulative proportion with recurrences or other events, to facilitate comparisons between different centres.
Persistent Identifierhttp://hdl.handle.net/10722/151476
ISSN
2015 Impact Factor: 3.487
2015 SCImago Journal Rankings: 1.314
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorHedley, AJen_US
dc.contributor.authorYoung, REen_US
dc.contributor.authorJones, SJen_US
dc.contributor.authorAlexander, WDen_US
dc.contributor.authorBewsher, PDen_US
dc.date.accessioned2012-06-26T06:23:45Z-
dc.date.available2012-06-26T06:23:45Z-
dc.date.issued1989en_US
dc.identifier.citationClinical Endocrinology, 1989, v. 31 n. 2, p. 209-218en_US
dc.identifier.issn0300-0664en_US
dc.identifier.urihttp://hdl.handle.net/10722/151476-
dc.description.abstractA study of antithyroid (ATD) therapy with a mean follow-up period of 10 years (range 2-25) in 434 patients with Graves'diseases has been made by linking hospital records with those of a central follow-up register. The majority (89%) were treated with carbimazole and 87% received combined therapy with triiodothyronine (T3) (73%) or thyroxine (T4) (14%). Sixty-one per cent were assessed for T3 suppression tests on completion of treatment, of whom 61% (95% CL, 55-67%) suppressed. The overall 5-year cumulative proportion developing recurrent hyperthyroidism was 54-62% with rates of 26-44% in suppressed patients and 65-79% in those not suppressed. In unsuppressed patients, most (72%) of the recurrences occurred within 1 year with only an additional 10% predicted up to 10 years. In suppressed patients 30% of recurrences occurred in the first year, 60% between 1 and 5 years and a further 10% between 5 and 10 years. Suppression with T3 is probably the best and cheapest predictor of outcome but has an accuracy of only 70% for both positive and negative tests which limits its usefulness in planning long-term follow-up and surveillance. A standard format should be adopted for the analysis and reporting of follow-up studies, based on actuarial methods of estimating the cumulative proportion with recurrences or other events, to facilitate comparisons between different centres.en_US
dc.languageengen_US
dc.publisherWiley-Blackwell Publishing Ltd.. The Journal's web site is located at http://www.wiley.com/bw/journal.asp?ref=0300-0664en_US
dc.relation.ispartofClinical Endocrinologyen_US
dc.subject.meshAdulten_US
dc.subject.meshAntithyroid Agents - Adverse Effects - Analysis - Therapeutic Useen_US
dc.subject.meshFemaleen_US
dc.subject.meshFollow-Up Studiesen_US
dc.subject.meshGraves Disease - Drug Therapy - Epidemiologyen_US
dc.subject.meshHumansen_US
dc.subject.meshHyperthyroidism - Drug Therapy - Epidemiologyen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshRecurrenceen_US
dc.subject.meshTime Factorsen_US
dc.titleAntithyroid drugs in the treatment of hyperthyroidism of Graves'disease: Long-term follow-up of 434 patientsen_US
dc.typeArticleen_US
dc.identifier.emailHedley, AJ:hrmrajh@hkucc.hku.hken_US
dc.identifier.authorityHedley, AJ=rp00357en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.pmid2481576-
dc.identifier.scopuseid_2-s2.0-0024402062en_US
dc.identifier.volume31en_US
dc.identifier.issue2en_US
dc.identifier.spage209en_US
dc.identifier.epage218en_US
dc.identifier.isiWOS:A1989AG85800010-
dc.publisher.placeUnited Kingdomen_US
dc.identifier.scopusauthoridHedley, AJ=7102584095en_US
dc.identifier.scopusauthoridYoung, RE=7405925753en_US
dc.identifier.scopusauthoridJones, SJ=7405931706en_US
dc.identifier.scopusauthoridAlexander, WD=7202232401en_US
dc.identifier.scopusauthoridBewsher, PD=7004559702en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats